Ga onbeperkt met Magzter GOLD

Ga onbeperkt met Magzter GOLD

Krijg onbeperkte toegang tot meer dan 9000 tijdschriften, kranten en Premium-verhalen voor slechts

$149.99
 
$74.99/Jaar

Poging GOUD - Vrij

Specialised Skill Development for GCCs in India

Bio Spectrum

|

BioSpectrum India May 2025

India is a key hub for Life Sciences and Healthcare (LSHC) Global Capability Centers (GCCs).

- Sudeep Krishna, Co-Founder & President, Healthark Insights

Specialised Skill Development for GCCs in India

With over 280,000 professionals, 40 per cent are focused on clinical research and using AI for healthcare advancements. The AI talent pool in India is projected to grow to 633,000 by 2025, emphasising the need for specialised skills and continuous learning to maintain its reputation as a top destination for LSHC GCCs.

India has solidified its position as a pivotal hub for Global Capability Centers (GCCs), especially in the Life Sciences and Healthcare (LSHC) sectors. These centres are instrumental in driving advancements in research and development, digital transformation, regulatory compliance, pharmacovigilance, clinical trial analytics, and supply chain management for global pharmaceutical and healthcare enterprises. To sustain this momentum, developing a workforce with specialised skills is essential. Currently, LSHC GCCs in India employ over 280,000 professionals. Of this talent pool, 43 per cent are engaged in core healthcare and R&D, 16 per cent specialise in IT, and 41 per cent focus on business process management.

This article delves into the initiatives undertaken for skill development, the contributions of industry leaders, emerging competencies, and the role of GCC consortiums in fortifying the talent pipeline for LSHC GCCs in India.

Escalating Demand for Specialised Skills in LSHC GCCs

As India cements its status as a preferred destination for LSHC GCCs, there is an escalating demand for professionals proficient in Regulatory Affairs & Compliance for navigating guidelines from authorities such as the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and Central Drugs Standard Control Organisation (CDSCO) of India for drug approvals; Clinical Research & Data Management for executing clinical trials, analysing real-world evidence, and managing extensive healthcare datasets.

MEER VERHALEN VAN Bio Spectrum

Bio Spectrum

Bio Spectrum

IASST synthesises new compound to combat aggressive breast cancer

A newly designed nitro-substituted organoselenium compound by Guwahati-based Institute of Advanced Study in Science and Technology (IASST), an autonomous institute under the Department of Science and Technology (DST), can reduce the invasiveness of aggressive triplenegative breast cancer cells by modulating various Se Se signalling pathways.

time to read

1 min

October 2025

Bio Spectrum

DPIIT signs MoU with Pfizer to strengthen healthcare innovation ecosystem

In a significant step towards strengthening India's healthcare innovation ecosystem, the Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry, has signed a Memorandum of Understanding (MoU) with Pfizer Limited.

time to read

1 min

October 2025

Bio Spectrum

Bio Spectrum

WHO unveils updated guideline on HIV service delivery

WHO has released an updated guideline to support integrated HIV service delivery, promote long-term adherence to antiretroviral therapy (ART), and improve the overall health and well-being of people living with HIV.

time to read

1 min

October 2025

Bio Spectrum

Scientists in Kolkata explore therapeutic potential of accessory proteins

A hidden protein that protects our cells from mechanical stress could provide a new direction to therapeutic strategies for diseases where protein stability under force is compromised like heart muscle disease or genetic disorders called laminopathies.

time to read

1 min

October 2025

Bio Spectrum

Bio Spectrum

US FDA advances rare disease drug development

The US Food and Drug Administration (FDA) has introduced the Rare Disease Evidence Principles (RDEP) to provide greater speed and predictability in the review of therapies intended to treat rare diseases with very small patient populations with significant unmet medical need and that are driven by a known genetic defect.

time to read

1 min

October 2025

Bio Spectrum

WHO updates list of essential medicines to include key cancer, diabetes treatments

The World Health Organization (WHO) has released updated editions of its Model Lists of Essential Medicines (EML) and Essential Medicines for Children (EMLC), adding new treatments for various types of cancer and for diabetes with associated comorbidities such as obesity.

time to read

1 min

October 2025

Bio Spectrum

Agilent's MMR IHC Panel pharmDx (Dako Omnis) receives European IVDR Certification

Agilent Technologies Inc. has announced that its MMR IHC Panel pharmDx (Dako Omnis) has received class C companion diagnostic (CDx) certification under EU in vitro diagnostic regulation (IVDR)1 as a CDx test for colorectal cancer.

time to read

1 min

October 2025

Bio Spectrum

Aodh Lifesciences gets support from TDB to redefine pneumonia treatment

The Technology Development Board (TDB), Department of Science and Technology, Government of India, has extended support to Aodh Lifesciences, a startup based in Hyderabad, for development of Indigenous Antibiotic Nebulisation Suspension for Pneumonia (AONEUM-04) and Antimicrobial Resistance (AMR).

time to read

1 min

October 2025

Bio Spectrum

Bio Spectrum

Antara Senior Care names Mukesh Ghuraiya as Chief Marketing Officer

Antara Senior Care, a fully integrated senior care ecosystem, has appointed Mukesh Ghuraiya as the Executive Vice-President and Chief Marketing Officer (CMO).

time to read

1 min

October 2025

Bio Spectrum

Poly Medicure acquires PendraCare Group for Rs 188.5 Cr

Poly Medicure, a Delhi-based medical device company, has announced signing of definitive agreements to acquire 90 per cent stake in PendraCare Group consisting of PendraCare Holdings and Welling Medical from Welling Holdings B.V. at an Enterprise value of Rs 188.5 crore (Euro 18.3 million).

time to read

1 min

October 2025

Listen

Translate

Share

-
+

Change font size